North America, particularly the United States, holds the largest revenue share in the Dry Age Related Macular Degeneration Amd Market, a dominance rooted in several powerful economic and structural factors. The region boasts the world's largest patient pool of dry AMD sufferers, driven by a significantly large and aging population (with a substantial portion aged 65-74, a high-prevalence demographic). High per-capita healthcare expenditure and a well-established infrastructure of specialized ophthalmic centers and retinal specialists ensure high diagnostic rates and rapid uptake of new, premium-priced therapeutics. Crucially, the US FDA has been the first regulatory body to approve the complement inhibitor drugs for Geographic Atrophy, giving the region a head start in market commercialization and adoption. Furthermore, robust public and private sector funding for biomedical research fuels a high concentration of pharmaceutical and biotech companies focused on developing innovative AMD solutions, from diagnostics to advanced therapies.

While North America maintains its leading position, the Asia-Pacific region is projected to register the fastest growth rate in the coming years. This is largely due to its immense, aging population, increasing disposable income, and the rapid expansion and modernization of its healthcare facilities. However, challenges related to drug accessibility, affordability, and the penetration of advanced treatments still need to be addressed in many APAC countries before it can rival the current commercial maturity of the North American market.